MDMA has kept up its strong reputation as a party drug for some time, but psychiatrists are finding out it’s so much more than just that. The Multidisciplinary Association for Psychedelic Studies (MAPS) just opened up five clinical trials to test the effectiveness of MDMA in treating PTSD. Results thus far have been overwhelmingly positive.
People who suffer from severe PTSD can now submit their name for potential MDMA-assisted psychotherapy. Scientists are seeking participants in four states for the five clinical trials, the final phase before the US Food and Drug Administration is able to approve the substance for medical use.
The following five trial sites are open for enrollment inquiries:
North Hollywood, California
Fort Collins, Colorado
New Orleans, Louisiana
Mount Pleasant, South Carolina
“If the Phase 3 trials demonstrate significant efficacy and an acceptable safety profile, FDA approval is expected by 2021,” according to MAPS. “Once approved, MDMA-assisted psychotherapy would only be available by prescription in supervised therapeutic settings from specially trained mental health providers.”
To see all of the requirements suitable subjects must meet, go here.